Cariprazine as adjunctive treatment in drug resistant obsessive compulsive disorder: A clinical trial
Not Applicable
- Conditions
- Health Condition 1: F422- Mixed obsessional thoughts and acts
- Registration Number
- CTRI/2023/06/053807
- Lead Sponsor
- Central Institute of Psychiatry
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients of either sex, aged between 18- 50 years.
2.Patients fulfilling ICD 10-DCR diagnostic criteria for Obsessive Compulsive Disorder but are drug resistant.
3.Patients giving written informed consent.
Exclusion Criteria
1.Any other major co-morbid psychiatric diagnoses (except mild to moderate depression, cut off as per HAM-D <18 and mild to moderate anxiety, cut off as per HAM-A <24) and substance dependence excluding nicotine & caffeine.
2.Presence of an acute/unstable medical or neurological condition.
3.Pregnancy or lactation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method effectiveness of Cariprazine in treatment of patients with drug resistant OCDTimepoint: baseline, 2weeks, 4 weeks, 6 weeks
- Secondary Outcome Measures
Name Time Method change in the levels of serum IL 1Beta and TNF alpha in patients receiving Cariprazine.Timepoint: baseline, 2weeks, 4 weeks, 6 weeks